Development of Hepatitis B surface antigen as a generic vector for the delivery of foreign CTL epitopes.

开发乙型肝炎表面抗原作为传递外源 CTL 表位的通用载体。

• 批准号: nhmrc : 401526
• 负责人: Prof Eric Gowans
• 金额: $ 29.32万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2006
• 资助国家: 澳大利亚
• 起止时间: 2006-01-01 至 2008-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-hepatitis-b-ctl-epitopes/77629
• 关键词: Development; Hepatitis; surface; antigen; generic

Many kinds of cancer and infections display unique proteins which the body's immune system can recognise as ' foreign', and mount an immune response which, if correctly harnessed, will kill the cancer or infected cells . A way to harness the immune response is to vaccinate with these unique proteins. However, new ways need to be found to deliver the unique proteins to produce the maximal possible anti- cancer or pathogen response, and one that is long lived. In particular one needs to stimulate the cellular arm of the immune response to produce killer cells named CTLs which specifically kill cancer or infected cells. In this project we plan to use an already-licensed human vaccine - the Hepatitis B surface antigen vaccine , or HBsAG, - and genetically modify it to contain important regions of cancer or pathogen proteins termed 'epitopes'. We surmise that immunisation with these modified HBsAg will elicit powerful CTL responses which will killer cancer or infected cells.

许多种类的癌症和感染显示出独特的蛋白质，身体的免疫系统可以将其识别为“外来”，并发起免疫反应，如果正确利用，将杀死癌症或受感染的细胞。利用免疫反应的一种方法是用这些独特的蛋白质接种疫苗。然而，需要找到新的方法来传递独特的蛋白质，以产生最大可能的抗癌或病原体反应，并且是长期存在的。特别是需要刺激免疫反应的细胞臂来产生被称为ctl的杀伤细胞，它专门杀死癌症或感染细胞。在这个项目中，我们计划使用一种已经获得许可的人类疫苗——乙型肝炎表面抗原疫苗（HBsAG），并对其进行基因修饰，使其包含被称为“表位”的癌症或病原体蛋白质的重要区域。我们推测用这些修饰的HBsAg免疫将引起强大的CTL反应，从而杀死癌症或感染细胞。